{"id":114306,"date":"2025-11-03T16:47:00","date_gmt":"2025-11-03T15:47:00","guid":{"rendered":"https:\/\/cms.munich-startup.net\/?p=114306"},"modified":"2025-11-03T15:37:48","modified_gmt":"2025-11-03T14:37:48","slug":"tubules-increase-series-c","status":"publish","type":"post","link":"https:\/\/cms.munich-startup.net\/en\/114306\/tubules-increase-series-c\/","title":{"rendered":"Tubulis increases Series C to 344 million euros"},"content":{"rendered":"<div class=\"entry-content\">\n<p>Just a few weeks after the announcement of the conclusion of a <a href=\"\/en\/113805\/tubulis-series-c\/\">Record funding round<\/a> Tubulis pulls off another coup. The biotech company increases its Series C funding by a further 36 million euros in the second closing, bringing the total volume to 344 million euros.<\/p>\n\n\n\n<p>The second closing brought additional new investors on board: Fidelity Management &amp; Research Company, Janus Henderson Investors, and Blackstone Multi-Asset Investing. They joined the consortium led by Venrock Healthcare Capital Partners. Wellington Management and Ascenta Capital also invested. Existing investors who supported the Series C funding round include Nextech Invest, EQT Life Sciences, Frazier Life Sciences, Andera Partners, Deep Track Capital, Bayern Kapital, Fund+, Occident, Seventure Partners, and High-Tech Gr\u00fcnderfonds (HTGF).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Tubulis aims to fully exploit its potential.<\/h2>\n\n\n\n<p>The additional funds are intended to support the clinical development of <a href=\"https:\/\/tubulis.com\/technology\/\" target=\"_blank\" rel=\"noreferrer noopener\">Antibody-drug conjugates (ADCs)<\/a> to further advance this approach. It involves a treatment for cancer that attacks cancer cells more precisely, efficiently, and with fewer side effects than conventional therapies. The leading ADC candidate, TUB-040, targets the NaPi2b antigen, which is found in ovarian and lung adenocarcinomas. Tubulis plans to initiate pivotal trials, explore previous lines of treatment, and investigate new combination therapies. The pipeline will also be expanded with TUB-030 and additional preclinical programs.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cWe are expanding our consortium with renowned investors, all of whom have a significant track record and a long-term strategic perspective. The combined funds will enable us to accelerate our clinical development plans and further expand our global footprint. We are now in a strong position to achieve our goal \u2013 to unlock the full potential of the ADC drug class for more patients.\u201d<\/p>\n<\/blockquote>\n\n\n\n<p>explained <strong>Dominik Schumacher<\/strong>, CEO and co-founder of Tubulis.<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Munich-based biotech company Tubulis is increasing its Series C financing round from 308 million euros to 344 million euros, thereby accelerating the development of its most promising ADC candidate.<\/p>","protected":false},"author":42,"featured_media":113806,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5633,1],"tags":[371,52,4001],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Tubulis erh\u00f6ht Series C auf 344 Millionen Euro - Munich Startup<\/title>\n<meta name=\"description\" content=\"Tubulis erh\u00f6ht seine Series-C-Finanzierung auf 344 Millionen Euro und treibt die klinische Entwicklung von TUB-040 voran.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cms.munich-startup.net\/en\/114306\/tubules-increase-series-c\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tubulis erh\u00f6ht Series C auf 344 Millionen Euro - Munich Startup\" \/>\n<meta property=\"og:description\" content=\"Tubulis erh\u00f6ht seine Series-C-Finanzierung auf 344 Millionen Euro und treibt die klinische Entwicklung von TUB-040 voran.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cms.munich-startup.net\/en\/114306\/tubules-increase-series-c\/\" \/>\n<meta property=\"og:site_name\" content=\"Munich Startup\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/munichstartup\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T15:47:00+00:00\" \/>\n<meta name=\"author\" content=\"Saskia Doll\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:site\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Saskia Doll\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cms.munich-startup.net\/114306\/tubulis-erhoeht-series-c\/\",\"url\":\"https:\/\/cms.munich-startup.net\/114306\/tubulis-erhoeht-series-c\/\",\"name\":\"Tubulis erh\u00f6ht Series C auf 344 Millionen Euro - Munich Startup\",\"isPartOf\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cms.munich-startup.net\/114306\/tubulis-erhoeht-series-c\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cms.munich-startup.net\/114306\/tubulis-erhoeht-series-c\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2025\/10\/Tubulis2.jpg\",\"datePublished\":\"2025-11-03T15:47:00+00:00\",\"author\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/a297bffde6879f56c9ff7b04d9af60b5\"},\"description\":\"Tubulis erh\u00f6ht seine Series-C-Finanzierung auf 344 Millionen Euro und treibt die klinische Entwicklung von TUB-040 voran.\",\"breadcrumb\":{\"@id\":\"https:\/\/cms.munich-startup.net\/114306\/tubulis-erhoeht-series-c\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cms.munich-startup.net\/114306\/tubulis-erhoeht-series-c\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/114306\/tubulis-erhoeht-series-c\/#primaryimage\",\"url\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2025\/10\/Tubulis2.jpg\",\"contentUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2025\/10\/Tubulis2.jpg\",\"width\":2400,\"height\":2147,\"caption\":\"Das Management-Team von Tubulis, (v. l. n. r.): Ingo Lehrke (CBO), G\u00fcnter Fingerle-Rowson (CMO), Dominik Schumacher (CEO), Jonas Helma-Smets (CSO), Matthew Norkunas (CFO) und Bj\u00f6rn Hock (CDO)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cms.munich-startup.net\/114306\/tubulis-erhoeht-series-c\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cms.munich-startup.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tubulis erh\u00f6ht Series C auf 344 Millionen Euro\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cms.munich-startup.net\/#website\",\"url\":\"https:\/\/cms.munich-startup.net\/\",\"name\":\"Munich Startup\",\"description\":\"Das offizielle Startup-Portal f\u00fcr M\u00fcnchen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cms.munich-startup.net\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/a297bffde6879f56c9ff7b04d9af60b5\",\"name\":\"Saskia Doll\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3cbbe2dd459d277864bc6c7477d0bdf8?s=96&d=blank&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3cbbe2dd459d277864bc6c7477d0bdf8?s=96&d=blank&r=g\",\"caption\":\"Saskia Doll\"},\"url\":\"https:\/\/cms.munich-startup.net\/en\/author\/doll\/\"}]}<\/script>\n<meta property=\"og:image\" content=\"https:\/\/cms.munich-startup.net\/en\/wp-content\/uploads\/2025\/10\/Tubulis2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2400\" \/>\n\t<meta property=\"og:image:height\" content=\"2147\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Tubulis increases Series C to 344 million euros - Munich Startup","description":"Tubulis increases its Series C funding to 344 million euros and advances the clinical development of TUB-040.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cms.munich-startup.net\/en\/114306\/tubules-increase-series-c\/","og_locale":"en_US","og_type":"article","og_title":"Tubulis erh\u00f6ht Series C auf 344 Millionen Euro - Munich Startup","og_description":"Tubulis erh\u00f6ht seine Series-C-Finanzierung auf 344 Millionen Euro und treibt die klinische Entwicklung von TUB-040 voran.","og_url":"https:\/\/cms.munich-startup.net\/en\/114306\/tubules-increase-series-c\/","og_site_name":"Munich Startup","article_publisher":"https:\/\/www.facebook.com\/munichstartup\/","article_published_time":"2025-11-03T15:47:00+00:00","author":"Saskia Doll","twitter_card":"summary_large_image","twitter_creator":"@munich_startup","twitter_site":"@munich_startup","twitter_misc":{"Written by":"Saskia Doll","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cms.munich-startup.net\/114306\/tubulis-erhoeht-series-c\/","url":"https:\/\/cms.munich-startup.net\/114306\/tubulis-erhoeht-series-c\/","name":"Tubulis increases Series C to 344 million euros - Munich Startup","isPartOf":{"@id":"https:\/\/cms.munich-startup.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cms.munich-startup.net\/114306\/tubulis-erhoeht-series-c\/#primaryimage"},"image":{"@id":"https:\/\/cms.munich-startup.net\/114306\/tubulis-erhoeht-series-c\/#primaryimage"},"thumbnailUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2025\/10\/Tubulis2.jpg","datePublished":"2025-11-03T15:47:00+00:00","author":{"@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/a297bffde6879f56c9ff7b04d9af60b5"},"description":"Tubulis increases its Series C funding to 344 million euros and advances the clinical development of TUB-040.","breadcrumb":{"@id":"https:\/\/cms.munich-startup.net\/114306\/tubulis-erhoeht-series-c\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cms.munich-startup.net\/114306\/tubulis-erhoeht-series-c\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/114306\/tubulis-erhoeht-series-c\/#primaryimage","url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2025\/10\/Tubulis2.jpg","contentUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2025\/10\/Tubulis2.jpg","width":2400,"height":2147,"caption":"Das Management-Team von Tubulis, (v. l. n. r.): Ingo Lehrke (CBO), G\u00fcnter Fingerle-Rowson (CMO), Dominik Schumacher (CEO), Jonas Helma-Smets (CSO), Matthew Norkunas (CFO) und Bj\u00f6rn Hock (CDO)"},{"@type":"BreadcrumbList","@id":"https:\/\/cms.munich-startup.net\/114306\/tubulis-erhoeht-series-c\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cms.munich-startup.net\/"},{"@type":"ListItem","position":2,"name":"Tubulis erh\u00f6ht Series C auf 344 Millionen Euro"}]},{"@type":"WebSite","@id":"https:\/\/cms.munich-startup.net\/#website","url":"https:\/\/cms.munich-startup.net\/","name":"Munich Startup","description":"The official startup portal for Munich","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cms.munich-startup.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/a297bffde6879f56c9ff7b04d9af60b5","name":"Saskia Doll","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3cbbe2dd459d277864bc6c7477d0bdf8?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3cbbe2dd459d277864bc6c7477d0bdf8?s=96&d=blank&r=g","caption":"Saskia Doll"},"url":"https:\/\/cms.munich-startup.net\/en\/author\/doll\/"}]},"og_image":[{"width":2400,"height":2147,"url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2025\/10\/Tubulis2.jpg","type":"image\/jpeg"}]},"_showyear":"","_inactive":"","_show_financing":"","_hide_on_map":"","_edit_lock":"1762509291:50","_edit_last":"42","_yoast_wpseo_focuskw":"Tubulis","_yoast_wpseo_metadesc":"Tubulis erh\u00f6ht seine Series-C-Finanzierung auf 344 Millionen Euro und treibt die klinische Entwicklung von TUB-040 voran.","_yoast_wpseo_linkdex":"85","_thumbnail_id":"113806","wbounce_status":"default","_yoast_wpseo_primary_category":"5633","_yoast_wpseo_focuskw_text_input":"","_yoast_wpseo_content_score":"90","ms_image_format":"contentwidth","_ms_image_format":"field_5cb8587572c8b","ms_dachzeile":"","_ms_dachzeile":"field_5cd9b7f365df5","ms_bump_post_date":"","_ms_bump_post_date":"field_5d1341edcf42a","guest_author_name":"","_guest_author_name":"field_5cee78a6016f9","guest_author_image":"","_guest_author_image":"field_5cee7914016fb","guest_author_description":"","_guest_author_description":"field_5cee78dd016fa","ms_post_image_caption":"","_ms_post_image_caption":"field_5f735b0735284","ms_post_image_credit":"","_ms_post_image_credit":"field_5f735b1435285","suppress_startupbox":"1","_suppress_startupbox":"field_60a64b0b6efc6","_yoast_wpseo_estimated-reading-time-minutes":"2","_wp_old_date":"","_yoast_wpseo_title":"","_yoast_wpseo_wordproof_timestamp":"","footnotes":"","easy_language_simplification_original_id":"","easy_language_source_language":"","easy_language_simplification_language":"","easy_language_api":"","easy_language_prevent_automatic_mode":"","_wp_old_slug":"","_wp_trash_meta_status":"","_wp_trash_meta_time":"","easy_language_simplification_state_changed_from":"","easy_language_de_EL_changed":"","ms_competition_deadline":"","_ms_competition_deadline":"","_wpbitly":"","enclosure":"","_yoast_wpseo_meta-robots-noindex":"","_yoast_wpseo_meta-robots-nofollow":"","wbounce_template":"","wbounce_title":"","wbounce_text":"","wbounce_cta":"","wbounce_url":"","wbounce_override":"","_yoast_wpseo_opengraph-title":"","_yoast_wpseo_opengraph-description":"","_oembed_7131efca3705e16bd9da2c41df237660":"","_oembed_time_7131efca3705e16bd9da2c41df237660":"","_pprredirect_type":"","_pprredirect_url":"","_yoast_wpseo_opengraph-image":"","_yoast_wpseo_opengraph-image-id":"","_newsletterglue":"","easy_language_text_language":"","_wp_desired_post_slug":"","_relevanssi_noindex_reason":"","_links":{"self":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/114306"}],"collection":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/users\/42"}],"replies":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/comments?post=114306"}],"version-history":[{"count":3,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/114306\/revisions"}],"predecessor-version":[{"id":114309,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/114306\/revisions\/114309"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media\/113806"}],"wp:attachment":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media?parent=114306"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/categories?post=114306"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/tags?post=114306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}